After intensive induction chemotherapy, 70—80% of young adult patients with newly diagnosed acute myeloid leukaemia (AML) achieve complete remission (CR); however, without additional treatment, most will relapse within a few months. Accordingly, the aim of post-remission treatment (PRT) is to eradicate residual disease, which persists after induction and is not detectable at examination of the bone marrow morphology.